TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 11696874
Drug: Inhaled iron
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled iron oxide particles with high soluble iron content
Study: 11696874
Drug: Inhaled iron
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled iron oxide particles with low soluble iron content
Study: 11696874
Drug: Inhaled iron
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled iron oxide particles (both high and low soluble iron)
Study: 20629971
Drug: D+/R- combination
Approvals — FDA: no, EMA: no, PMDA: no
Description: D+/R- combination
Study: 1593749
Drug: Pimobendan (2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pimobendan (2.5 mg, intravenous)
Study: 1593749
Drug: Captopril (12.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Captopril (12.5 mg, orally)
Study: 6321686
Drug: Chemotherapy plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy plus tamoxifen (20 mg/m2 on days 2-6) and premarin (0.625 mg every 12 hours for three days on day 7)
Study: 6321686
Drug: Chemotherapy (cytoxan
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy (cytoxan 750 mg/m2 and Adriamycin 30 mg/m2 on day 1 plus 5‐fluorouracil 500 mg/m2 and methotrexate 40 mg/m2 on day 8)
Study: 26516308
Drug: Magnesium sulphate
Normalized name: Magnesium sulphate
DrugBank: Magnesium (DB14513)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Magnesium sulphate 30 mg/kg followed by 10 mg/kg/h continuous infusion until the end of surgery
Study: 21291422
Drug: Propofol treatment
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Propofol treatment (group P)
Study: 21291422
Drug: Isoflurane treatment
Normalized name: Isoflurane
DrugBank: Isoflurane (DB00753)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Isoflurane treatment (group I)
Study: 17121064
Drug: Sertaconazole nitrate
Normalized name: Sertaconazole Nitrate
DrugBank: Sertaconazole (DB01153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sertaconazole nitrate cream 2% applied twice daily for 4 weeks
Study: 17121064
Drug: Vehicle control
Normalized name: meningococcal group B vaccine / Neisseria meningitidis serogroup B recombinant FHBP fusion protein antigen / Neisseria meningitidis serogroup B recombinant NHBA fusion protein antigen / Neisseria meningitidis serogroup B strain NZ98/254 outer membrane vesicle Prefilled Syringe [Bexsero]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vehicle control applied twice daily for 4 weeks
Study: 12734156
Drug: Morphine PCA
Normalized name: lauryl PCA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morphine PCA alone (Group I, n = 15)
Study: 12734156
Drug: Morphine PCA
Normalized name: lauryl PCA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morphine PCA plus a continuous basal infusion (Group II, n = 14)
Study: 10348755
Drug: Delavirdine monotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Delavirdine monotherapy (low target arm)
Study: 10348755
Drug: Delavirdine monotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Delavirdine monotherapy (middle target arm)
Study: 10348755
Drug: Delavirdine monotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Delavirdine monotherapy (high target arm)
Study: 10348755
Drug: Delavirdine monotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Delavirdine monotherapy (pooled arms)
Study: 10348755
Drug: Nucleoside control
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nucleoside control therapy (zidovudine or didanosine)
Study: 8664036
Drug: 5-fluorouracil (5-FU)
Normalized name: 5-FU
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 5-fluorouracil (5-FU) 200 or 300 mg/m2/day by prolonged ambulatory infusion with radiotherapy (60-66 Gy)
Study: 1960007
Drug: High-dose yohimbine
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose yohimbine (peak dose, 43 mg/day)
Study: 6264376
Drug: Glucose-containing oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glucose-containing oral rehydration solution
Study: 6264376
Drug: Sucrose-containing oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sucrose-containing oral rehydration solution
Study: 6264376
Drug: Both glucose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both glucose and sucrose solutions
Study: 6500778
Drug: Vincamine teprosilate
Normalized name: vincamine
DrugBank: Vincamine (DB13374)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vincamine teprosilate (Teproside) at 120 mg daily for 90 days
Study: 30157910
Drug: Zoledronic acid
Normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Zoledronic acid (ZA) alongside chemotherapy
Study: 30157910
Drug: Placebo alongside
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo alongside chemotherapy
Study: 30157910
Drug: Non-randomised open-label
Normalized name: Tavist Non-Sedating
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-randomised open-label arm (ZA or placebo for those who decline chemotherapy)
Study: 20423524
Drug: Telephone-based intervention
Approvals — FDA: no, EMA: no, PMDA: no
Description: Telephone-based intervention consisting of print resources and four weekly 30-minute telephone support calls.
Study: 16140526
Drug: Amifostine (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amifostine (500 mg subcutaneously)
Study: 16140526
Drug: Amifostine administration
Normalized name: Amifostine
DrugBank: Amifostine (DB01143)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amifostine administration
Study: 14642140
Drug: L-thyroxine (L-T(50))
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-thyroxine (L-T(50))
Study: 10430112
Drug: 400 mg
Normalized name: mesna 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg celecoxib twice a day
Study: 10430112
Drug: 500 mg
Normalized name: bran 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 mg naproxen twice a day
Study: 7555513
Drug: 50/50 human
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50/50 human insulin mixture (0.3 U/kg)
Study: 7555513
Drug: 70/30 human
Approvals — FDA: no, EMA: no, PMDA: no
Description: 70/30 human insulin mixture (0.3 U/kg)
Study: 2188525
Drug: Epidural morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural morphine with 2.5 mg droperidol
Study: 2188525
Drug: Epidural morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural morphine with placebo
Study: 6457384
Drug: Needle acupuncture
Normalized name: NEEDLE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Needle acupuncture at correct sites according to Chinese medicine
Study: 14722446
Drug: 10‐mg once‐daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10‐mg once‐daily topical regimen of miconazole nitrate mucoadhesive buccal tablet (n = 178)
Study: 14722446
Drug: 400‐mg once‐daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400‐mg once‐daily systemic regimen of ketoconazole (n = 179)
Study: 14722446
Drug: 10‐mg once‐daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10‐mg once‐daily topical regimen of miconazole nitrate mucoadhesive buccal tablet
Study: 14722446
Drug: 400‐mg once‐daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400‐mg once‐daily systemic regimen of ketoconazole
Study: 11095468
Drug: Transdermal estradiol
Normalized name: estradiol Transdermal System
DrugBank: Estradiol (DB00783)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Transdermal estradiol supplementation (TES); n = 10; Estraderm, 50 microg/24 h
Study: 8250719
Drug: Hydrocortisone sodium
Normalized name: Hydrocortisone Sodium Phosphate
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Hydrocortisone sodium succinate (HCSS) 5 mg hydrocortisone/kg body weight
Study: 8250719
Drug: Epinephrine (0.004
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epinephrine (0.004 mg/kg)
Study: 3898836
Drug: Induction therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Induction therapy with carmustine, cyclophosphamide, and prednisone
Study: 26867083
Drug: Therapist-guided internet-based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Therapist-guided internet-based cognitive-behavioral treatment (iCBT)
Study: 23488876
Drug: 3.57 ml/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3.57 ml/kg energy drink (ED)
Study: 21774589
Drug: 1,000 mg
Normalized name: bran 1,000 mg ORAL WAFER
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1,000 mg of elemental calcium with 400 IU vitamin D3
Study: 16426291
Drug: Flutivate cream
Normalized name: fluticasone Topical Cream [Cutivate]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flutivate cream containing FA
Study: 16426291
Drug: Betnovate cream
Normalized name: Betnovate
DrugBank: Betamethasone (DB00443)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Betnovate cream not containing FA
Study: 11246305
Drug: N-acetylcysteine (NAC)
DrugBank: Acetylcysteine (DB06151)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: N-acetylcysteine (NAC) high-dose treatment (6 g on day 1, 12 g on day 2, 18 g on days 3 and 4)
Study: 11246305
Drug: N-acetylcysteine (NAC)
DrugBank: Acetylcysteine (DB06151)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: N-acetylcysteine (NAC) high-dose treatment
Study: 11246305
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (mucolytic basis dosage of NAC 3 x 300 mg/day)
Study: 9038857
Drug: 0.025 mg
Normalized name: lisuride 0.025 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.025 mg rhGH/kg once daily
Study: 9038857
Drug: rhIGF-I at
Normalized name: rhIGF-I/rhIGFBP-3
DrugBank: Mecasermin rinfabate (DB14751)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: rhIGF-I at 0.015 mg/kg twice daily (low dose)
Study: 9038857
Drug: rhIGF-I at
Normalized name: rhIGF-I/rhIGFBP-3
DrugBank: Mecasermin rinfabate (DB14751)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: rhIGF-I at 0.03 mg/kg twice daily (mid dose)
Study: 9038857
Drug: rhIGF-I at
Normalized name: rhIGF-I/rhIGFBP-3
DrugBank: Mecasermin rinfabate (DB14751)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: rhIGF-I at 0.06 mg/kg twice daily (high dose)
Study: 9038857
Drug: mid dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: mid dose rhIGF-I
Study: 9038857
Drug: high dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: high dose rhIGF-I
Study: 2644150
Drug: Cisapride (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cisapride (10 mg t.i.d.)
Study: 25909710
Drug: Mesna (360
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mesna (360 mg/m2) co-administered with doxorubicin
Study: 25909710
Drug: Saline co-administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline co-administered with doxorubicin
Study: 24781527
Drug: 150 mg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150 mg/day erlotinib or a body weight-adjusted dose with subsequent escalations to 200 mg/day
Study: 22366136
Drug: 0.5% chemically
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5% chemically modified lignin in diet contaminated with 7.9 mg/kg ZEA
Study: 22366136
Drug: Diet contaminated
Normalized name: phentermine hydrochloride Oral Capsule [T-Diet]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diet contaminated with 7.9 mg/kg ZEA
Study: 22366136
Drug: 0.5% lignin
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5% lignin in diet contaminated with 7.9 mg/kg ZEA
Study: 15696578
Drug: Etanercept (0.4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Etanercept (0.4 mg/kg) administered subcutaneously twice weekly for 6 months
Study: 15696578
Drug: Placebo administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo administered subcutaneously twice weekly for 6 months
Study: 10501986
Drug: Topical miotics
Normalized name: nystatin / triamcinolone acetonide Topical Ointment [Myco Biotic]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical miotics (n = 28)
Study: 2592580
Drug: Verapamil (80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Verapamil (80 mg every 8 hours)
Study: 3555370
Drug: Verapamil (drug
Approvals — FDA: no, EMA: no, PMDA: no
Description: Verapamil (drug levels higher than 150 ng/ml)
Study: 3555370
Drug: Verapamil (drug
Approvals — FDA: no, EMA: no, PMDA: no
Description: Verapamil (drug levels lower than 150 ng/ml)
Study: 29042456
Drug: Immunosuppressive combination
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immunosuppressive combination
Study: 24935517
Drug: Midazolam and
Normalized name: Midazolam
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Midazolam and Propofol (sequential use)
Study: 20552171
Drug: TFMPP 60
Approvals — FDA: no, EMA: no, PMDA: no
Description: TFMPP 60 mg
Study: 15917266
Drug: Extract of
Normalized name: Extract of tomato
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extract of Cajanus cajan (Ciklavit) administered twice daily for 6 months
Study: 15917266
Drug: Placebo administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo administered twice daily for 6 months
Study: 8731235
Drug: 300 mg
Normalized name: rutin 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 mg etodolac b.i.d for three days after a 36-hour placebo washout
Study: 8731235
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg indomethacin b.i.d for three days after a 36-hour placebo washout
Study: 8298199
Drug: ALN 10
Normalized name: ALN-AT3SC
DrugBank: Fitusiran (DB15002)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ALN 10 mg daily
Study: 8298199
Drug: ALN 20
Normalized name: ALN-AT3SC
DrugBank: Fitusiran (DB15002)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ALN 20 mg daily
Study: 8298199
Drug: CT 100
Normalized name: B-Ject 100
Approvals — FDA: no, EMA: no, PMDA: no
Description: CT 100 IU daily
Study: 3080510
Drug: Astemizole (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Astemizole (10 mg every day)
Study: 27442155
Drug: Low-dose inhaled
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose inhaled nitric oxide (iNO) starting at 5 parts per million, maintenance dose of 2 parts per million for ⩾7 days (n=162)
Study: 24337471
Drug: Expanded School
Normalized name: schorl tourmaline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Expanded School Mental Health (ESMH) treatment
Study: 22985572
Drug: Remifentanil 0.05
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remifentanil 0.05 µg·kg(‐1)·min(‐1)
Study: 22985572
Drug: Remifentanil 0.10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remifentanil 0.10 µg·kg(‐1)·min(‐1)
Study: 22985572
Drug: Remifentanil 0.20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remifentanil 0.20 µg·kg(‐1)·min(‐1)
Study: 22985572
Drug: No drug
Approvals — FDA: no, EMA: no, PMDA: no
Description: No drug (Control group D)
Study: 20637962
Drug: Banana-flavored suspension
Approvals — FDA: no, EMA: no, PMDA: no
Description: Banana-flavored suspension
Study: 10687570
Drug: Daily smoking
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily smoking relapse postpartum
Study: 1897811
Drug: Fluticasone propionate
Normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Fluticasone propionate aqueous nasal spray 200 micrograms QD
Study: 1897811
Drug: Fluticasone propionate
Normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Fluticasone propionate aqueous nasal spray 100 micrograms BID
Study: 6291802
Drug: Clonidine, 0.3
Normalized name: Clonidine, 0.3 mg/24 hr transdermal film, extended release
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clonidine, 0.3 mg/day orally for 3 days
Study: 6291802
Drug: Naloxone, 0.4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naloxone, 0.4 mg intravenously on the third day of clonidine treatment
Study: 26365823
Drug: Vitamin D
Normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin D auxiliary rehabilitation therapy
Study: 26179090
Drug: GSK2374697 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: GSK2374697 2 mg
Study: 24368086
Drug: Single vaccination
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single vaccination with rHVT‐ND vaccine at one day of age
Study: 24368086
Drug: Single vaccination
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single vaccination with rHVT‐ND vaccine
Study: 24368086
Drug: Booster vaccination
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Booster vaccination of rHVT‐ND vaccinated birds with conventional ND vaccines
Study: 23866474
Drug: Oral clonidine
Normalized name: Clonidine
DrugBank: Clonidine (DB00575)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral clonidine (5 g/kg)
Study: 17513652
Drug: parecoxib 40
Normalized name: Parécoxib
DrugBank: Parecoxib (DB08439)
Approvals — FDA: no, EMA: yes, PMDA: no
Description: parecoxib 40 mg at induction, placebo at wound closure, parecoxib 40 mg 12 h after induction (pre)
Study: 17513652
Drug: placebo at
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo at induction, parecoxib 40 mg at wound closure, parecoxib 40 mg 12 h after induction (post)
Study: 15378186
Drug: Intrarectal amifostine
Normalized name: Amifostine
DrugBank: Amifostine (DB01143)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intrarectal amifostine (1,500 mg in a 40-ml enema)
Study: 11744585
Drug: Preemptive analgesia
Normalized name: Analgesic Balm GRX
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preemptive analgesia (multi-modal therapy)
Study: 9850014
Drug: Single-agent therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-agent therapy
Study: 9852695
Drug: Propofol (P
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propofol (P group) - 2.5 mg.kg‐1 with 0.2 microgram.kg‐1 fentanyl
Study: 4712484
Drug: Intravenous atropine
Normalized name: Atropine
DrugBank: Atropine (DB00572)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous atropine with propanidid
Study: 30992200
Drug: Cinnamomum zeylanicum
Normalized name: Cinnamomum camphora resin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cinnamomum zeylanicum extract at 4 mg/mL
Study: 30992200
Drug: Cinnamomum zeylanicum
Normalized name: Cinnamomum camphora resin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cinnamomum zeylanicum extract at 2 mg/mL
Study: 18804330
Drug: Intranasal insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intranasal insulin (40 I.U.)
Study: 1340550
Drug: Subcutaneous salbutamol
Normalized name: salbutamol
DrugBank: Albuterol (DB01001)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Subcutaneous salbutamol (0.5 mg)
Study: 31437695
Drug: 0.5 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 mg/kg ketamine (standard dose)
Study: 31437695
Drug: 0.2 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.2 mg/kg ketamine (low dose)
Study: 29794060
Drug: Bilateral deep
Normalized name: Deep Sea
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bilateral deep brain stimulation (DBS) targeting the anterior limb of the internal capsule in nondiabetic patients.
Study: 29794060
Drug: Optogenetic activation
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Optogenetic activation of dopamine D1 receptor-expressing neurons in the nucleus accumbens in mice.
Study: 25348346
Drug: Integrated care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Integrated care including treatment as usual plus a psychoeducational intervention (14 sessions)
Study: 25348346
Drug: Treatment as
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment as usual (pharmacotherapy and regular sessions with psychiatrist)
Study: 17631702
Drug: rhGH treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: rhGH treatment (10 U hypodermically daily for 10 days)
Study: 29316154
Drug: Oral nifedipine
Normalized name: Nifedipine
DrugBank: Nifedipine (DB01115)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral nifedipine (n=71)
Study: 29316154
Drug: Intravenous labetalol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous labetalol (n=72)
Study: 27590259
Drug: Riociguat (Adempas®,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Riociguat (Adempas®, BAY 63‐2521) administered over 26 weeks
Study: 22361121
Drug: Gaviscon® (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gaviscon® (4 × 10 mL/day)
Study: 17644123
Drug: Local therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Local therapy for select patients with increasing PSA values below 1.0 ng/ml and lower Gleason score neoplasms.
Study: 7542675
Drug: Loratadine (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Loratadine (20 mg)
Study: 347569
Drug: Valproate with
Normalized name: valproate
DrugBank: Valproic acid (DB00313)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Valproate with reduced phenobarbital dose (by about 40%)
Study: 30964527
Drug: Standard-dose vitamin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard-dose vitamin D3
Study: 26172084
Drug: Insulin glargine
Normalized name: Insulin Glargine
DrugBank: Insulin glargine (DB00047)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Insulin glargine 100 U/ml (Gla-100)
Study: 14687141
Drug: Nurse-administered propofol
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nurse-administered propofol
Study: 2444307
Drug: Bromocriptine 2.5
Normalized name: bromocriptine 2.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bromocriptine 2.5 mg and 5 mg
Study: 28414488
Drug: Treatment for
Normalized name: Hair Regrowth Treatment For Men
DrugBank: Minoxidil (DB00350)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Treatment for Self-Injurious Behaviors (T-SIB); n = 15
Study: 28414488
Drug: Treatment as
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment as usual; n = 18
Study: 16418308
Drug: Dacarbazine (DTIC)
Normalized name: Dacarbazine
DrugBank: Dacarbazine (DB00851)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dacarbazine (DTIC) 850 mg/m2 intravenously every 4 weeks
Study: 16418308
Drug: Dacarbazine (DTIC)
Normalized name: Dacarbazine
DrugBank: Dacarbazine (DB00851)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dacarbazine (DTIC) chemotherapy
Study: 7955182
Drug: Heparin plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparin plus antithrombin III (250 U heparin + 25 U antithrombin III per minute)
Study: 7955182
Drug: Heparin alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparin alone (250 U heparin per minute)
Study: 7955182
Drug: Heparin plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparin plus antithrombin III
Study: 23772532
Drug: Continuous infusion
Normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous infusion of low-dose remifentanil (0.02, 0.05, and 0.07 microg x kg ‐1 x hr‐1)
Study: 23772532
Drug: Continuous infusion
Normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous infusion of low-dose remifentanil